Metrikler
Yayın
44
Açık Erişim
4
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (39)
SCI-E, SSCI, AHCI (39)
SCI-E, SSCI, AHCI, ESCI (39)
Scopus (39)
TRDizin (3)
2024
20241. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY
, 2024 (SCI-Expanded, Scopus)
2024
20242. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.
Clinical Genitourinary Cancer
, cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)
2024
20243. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Machiels J., Tao Y., Licitra L., Burtness B., Tahara M., Rischin D., et al.
The Lancet Oncology
, 2024 (SCI-Expanded, Scopus)
2024
20244. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.
Cancer Medicine
, cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)
2024
20245. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
Yildirim M. E., Karadurmuş N., Ökten İ. N., TÜRK H. M., Urakçı Z., Arslan Ç., et al.
Journal of Oncology Pharmacy Practice
, 2024 (SCI-Expanded, Scopus)
2023
20236. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.
Medicine
, cilt.102, sa.45, 2023 (SCI-Expanded, Scopus)
2023
20237. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
Erol C., Yekedüz E., Tural D., Karakaya S., Şentürk Öztaş N., Uçar G., et al.
Urologia Internationalis
, cilt.107, sa.6, ss.595-601, 2023 (SCI-Expanded, Scopus)
2023
20238. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al.
Clinical Genitourinary Cancer
, cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)
2022
20229. Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data
Karadurmus N., Yildirim E., Yalcin S., Gumus M., Bilir C., Cubukcu E., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.4, 2022 (SCI-Expanded, Scopus)
2022
202210. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.6, 2022 (SCI-Expanded, Scopus)
2021
202111. Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.
Kefeli U., Arslan C., Yildirim M. E., Isikdogan A., Karadurmus N., Karabulut B., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)
2020
202012. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.
Disel U., Kose F., Bilici A., Ozguroglu M., Saglam S., Seker M., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)
2017
201713. Prognostic role of inflammatory biomarkers in metastatic breast cancer
Petekkaya I., Unlu O., Roach E. C., Gecmez G., Okoh A. K., BABACAN T., et al.
JOURNAL OF BUON
, cilt.22, sa.3, ss.614-622, 2017 (SCI-Expanded, Scopus)
2014
201414. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update
Arslan C., Dizdar O., ALTUNDAG K.
EXPERT OPINION ON PHARMACOTHERAPY
, cilt.15, sa.12, ss.1643-1658, 2014 (SCI-Expanded, Scopus)
2013
201315. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy
OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
, cilt.31, sa.8, ss.1709-1715, 2013 (SCI-Expanded, Scopus)
2013
201316. Association of breast cancer subtypes and body mass index
Petekkaya I., ŞAHİN U., Gezgen G., Solak M., YÜCE D., DİZDAR Ö., et al.
TUMORI J
, cilt.99, sa.2, ss.129-133, 2013 (SCI-Expanded, Scopus)
2012
201217. Does Androgen Receptor Have a Prognostic Role in Patients with Estrogen/Progesterone-Negative and c-erbB-2-Positive Breast Cancer?
Arslan C., Isik M., GÜLER G., Kulac I., Solak M., Turker B., et al.
AMERICAN SURGEON
, cilt.78, sa.9, ss.992-999, 2012 (SCI-Expanded, Scopus)
2012
201218. Frequency of HCV infection in renal cell carcinoma patients
Budakoglu B., Aksoy S., ARSLAN Ç., Uyeturk U., Babacan N. A., Ozcan M. F., et al.
MEDICAL ONCOLOGY
, cilt.29, sa.3, ss.1892-1895, 2012 (SCI-Expanded, Scopus)
2012
201219. Increased mean corpuscular volume of erythrocytes predicts the response to metronomic cyclophosphamide, capecitabine and bevacizumab treatment: Is it true for capecitabine treatment or more?
Arslan C., Altundag K.
BREAST
, cilt.21, sa.4, ss.612-613, 2012 (SCI-Expanded, Scopus)
2012
201220. Pituitary Gland Metastasis of Breast Cancer: A Case Report
Ozkan C., ARSLAN Ç., KILIÇ M., ERMAN M., Altundag K.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.22, sa.1, ss.42-45, 2012 (SCI-Expanded, Scopus, TRDizin)
2012
201221. Screening Colonoscopy Participation in Turkish Colorectal Cancer Patients and their First Degree Relatives
KILIÇKAP S., ARSLAN Ç., Rama D., YALÇIN Ş.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.13, sa.6, ss.2829-2832, 2012 (SCI-Expanded, Scopus)
2011
201122. Emerging drugs in metastatic breast cancer: an update
Arslan C., Altundag K., Dizdar O.
EXPERT OPINION ON EMERGING DRUGS
, cilt.16, sa.4, ss.647-667, 2011 (SCI-Expanded, Scopus)
2011
201123. Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer
BULUT N., AKSOY S., DİZDAR Ö., Dede D. S., Arslan C., DOĞAN E., et al.
MEDICAL ONCOLOGY
, cilt.28, 2011 (SCI-Expanded, Scopus)
2011
201124. Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response
ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., et al.
TUMORI
, cilt.97, sa.6, ss.711-716, 2011 (SCI-Expanded, Scopus)
2011
201125. Acute promyelocytic leukemia in a young patient with breast cancer
KARA O., Ozdemir E., Arslan C., DOGAN E., ALTUNDAG K.
MEDICAL ONCOLOGY
, cilt.28, sa.1, ss.249-250, 2011 (SCI-Expanded, Scopus)
2011
201126. Zoledronic acid and atrial fibrillation in cancer patients
ARSLAN Ç., AKSOY S., DİZDAR Ö., Dede D. S., HARPUTLUOĞLU H., ALTUNDAĞ M. K.
SUPPORTIVE CARE IN CANCER
, cilt.19, sa.3, ss.425-430, 2011 (SCI-Expanded, Scopus)
2011
201127. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature
ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.22, sa.1, ss.73-76, 2011 (SCI-Expanded, Scopus, TRDizin)
2011
201128. FREQUENCY OF CANCER TYPES IN PATIENTS AGED 65 AND OLDER: RESULTS FROM CANCER REGISTRY DATABASE OF HACETTEPE UNIVERSITY HOSPITALS
Arslan C., KILIÇKAP S., Dede D. S., HAYRAN K. M., ERMAN M., ÇELİK İ., et al.
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
, cilt.14, sa.3, ss.187-192, 2011 (SCI-Expanded, SSCI, Scopus, TRDizin)
2011
201129. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature
Arslan C., Sari E., Aksoy S., Altundag K.
EXPERT OPINION ON THERAPEUTIC TARGETS
, cilt.15, sa.1, ss.21-30, 2011 (SCI-Expanded, Scopus)
2010
201030. Other malignancies in patients with breast cancer: a single institute experience
Dogan E., AKSOY S., DİZDAR Ö., ŞENER DEDE D., ARSLAN Ç., Ozisik Y., et al.
MEDICAL ONCOLOGY
, cilt.27, sa.4, ss.1434-1435, 2010 (SCI-Expanded, Scopus)
2010
201031. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma
Dogan E., AKSOY S., ARSLAN Ç., ŞENER DEDE D., Altundag K.
MEDICAL ONCOLOGY
, cilt.27, sa.4, ss.1436-1437, 2010 (SCI-Expanded, Scopus)
2010
201032. Serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of diagnosis
ŞENER DEDE D., ARSLAN Ç., Altundag K.
MEDICAL ONCOLOGY
, cilt.27, sa.4, ss.1429, 2010 (SCI-Expanded, Scopus)
2010
201033. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perpectives
Tonyali O., ARSLAN Ç., Altundag K.
EXPERT OPINION ON PHARMACOTHERAPY
, cilt.11, sa.16, ss.2715-2725, 2010 (SCI-Expanded, Scopus)
2010
201034. The Effect on Prognosis of Postoperative CA 19-9 Level in Patients With Pancreatic Cancer
KILIÇKAP S., ARSLAN Ç.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.33, sa.3, ss.320, 2010 (SCI-Expanded, Scopus)
2010
201035. Systemic treatment in breast-cancer patients with brain metastasis
Arslan C., DİZDAR Ö., Altundag K.
EXPERT OPINION ON PHARMACOTHERAPY
, cilt.11, sa.7, ss.1089-1100, 2010 (SCI-Expanded, Scopus)
2010
201036. Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma
KILIÇKAP S., ARSLAN Ç., ŞENEL S., ATASEVEN H.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.28, sa.6, 2010 (SCI-Expanded, Scopus)
2010
201037. Estrogen receptor immunohistochemistry cutoff value: Standardization is needed
ARSLAN Ç., DİZDAR Ö., Altundag K.
HUMAN PATHOLOGY
, cilt.41, sa.1, ss.150, 2010 (SCI-Expanded, Scopus)
2009
200938. Pharmacotherapy of triple-negative breast cancer
ARSLAN Ç., DİZDAR Ö., Altundag K.
EXPERT OPINION ON PHARMACOTHERAPY
, cilt.10, sa.13, ss.2081-2093, 2009 (SCI-Expanded, Scopus)
2009
200939. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
KILIÇKAP S., ARSLAN Ç.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
, cilt.301, sa.14, ss.1435, 2009 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2013
20131. Early stage "T2N0" breast cancer: Does it consist two different "T2" stages?
Arslan C., Sahin U., Kizilarslanoglu C., Solak M., Gullu I. H., Ozisik Y., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
20132. Clinicopathologic characteristics of pure papillary breast carcinoma
Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
20133. Inflammatory markers in metastatic breast cancer.
Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2012
20124. Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors.
Sahin U., Petekkaya I., Arslan C., Sarici S. F., Solak M., Keskin O., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
20125. Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.
Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)